| Omegie Linda Anabor, MD | |
|
1602 Garth Rd, Baytown, TX 77520-2410 | |
| (281) 837-2700 | |
| Not Available |
| Full Name | Omegie Linda Anabor |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 1602 Garth Rd, Baytown, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184971723 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | Q5964 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harris Health System | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ut Physicians | 8426960360 | 1400 |
News Archive
Inter Press Service reports on "a conference organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on World Cancer Day [February 4] in Geneva," during which experts warned about the growing burden of non-communicable diseases (NCDs) - "cancer, heart disease, diabetes and chronic respiratory diseases, among others" - especially in low- and middle-income countries.
On Anosmia Awareness Day, the Monell Center announces "A Sense of Hope: The Monell Anosmia Project," a three-year $1.5M fundraising campaign to support a research and advocacy program focused on anosmia, the loss of the sense of smell.
Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online.
A $500,000 grant from the National Science Foundation will allow the Harold W. Manter Laboratory of Parasitology to digitally preserve four major collections of parasite specimens donated to the University of Nebraska-Lincoln during the past five years.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
› Verified 1 days ago
| Entity Name | Ut Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033157821 PECOS PAC ID: 8426960360 Enrollment ID: O20031107000268 |
News Archive
Inter Press Service reports on "a conference organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on World Cancer Day [February 4] in Geneva," during which experts warned about the growing burden of non-communicable diseases (NCDs) - "cancer, heart disease, diabetes and chronic respiratory diseases, among others" - especially in low- and middle-income countries.
On Anosmia Awareness Day, the Monell Center announces "A Sense of Hope: The Monell Anosmia Project," a three-year $1.5M fundraising campaign to support a research and advocacy program focused on anosmia, the loss of the sense of smell.
Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online.
A $500,000 grant from the National Science Foundation will allow the Harold W. Manter Laboratory of Parasitology to digitally preserve four major collections of parasite specimens donated to the University of Nebraska-Lincoln during the past five years.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Omegie Linda Anabor, MD 1602 Garth Rd, Baytown, TX 77520-2410 Ph: (281) 837-2700 | Omegie Linda Anabor, MD 1602 Garth Rd, Baytown, TX 77520-2410 Ph: (281) 837-2700 |
News Archive
Inter Press Service reports on "a conference organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on World Cancer Day [February 4] in Geneva," during which experts warned about the growing burden of non-communicable diseases (NCDs) - "cancer, heart disease, diabetes and chronic respiratory diseases, among others" - especially in low- and middle-income countries.
On Anosmia Awareness Day, the Monell Center announces "A Sense of Hope: The Monell Anosmia Project," a three-year $1.5M fundraising campaign to support a research and advocacy program focused on anosmia, the loss of the sense of smell.
Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online.
A $500,000 grant from the National Science Foundation will allow the Harold W. Manter Laboratory of Parasitology to digitally preserve four major collections of parasite specimens donated to the University of Nebraska-Lincoln during the past five years.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
› Verified 1 days ago
Aziza Q Hasan, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1602 Garth Rd, 250, Baytown, TX 77520 Phone: 281-837-2700 | |
Dr. Haider Afzal, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1690 W Baker Rd, Ste B, Baytown, TX 77521 Phone: 281-428-8203 Fax: 281-428-0624 | |
Dr. Kent E Anthony, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4301 Garth Rd, Suite 400, Baytown, TX 77521 Phone: 281-420-8400 Fax: 713-523-4897 | |
Dr. Kelly A Gabler, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4301 Garth Rd, Suite 400, Baytown, TX 77521 Phone: 281-420-8400 | |
Eli Newsome, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4301 Garth Rd, 302, 306 And 400, Baytown, TX 77521 Phone: 832-548-5000 | |
Anthony Capili, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9825 Eagle Dr, Baytown, TX 77523 Phone: 281-576-0670 Fax: 409-267-4443 | |
Mr. Geoffrey Ali Jahan- Tigh, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4310 Garth Rd, Baytown, TX 77521 Phone: 281-425-6965 Fax: 832-556-2925 |